Skip to main content

Table 6 The outcomes of TCZ and SAR

From: Drug-induced liver injury following the use of tocilizumab or sarilumab in patients with coronavirus disease 2019

Outcome

TCZ (N, %)

SAR (N, %)

Congenital anomaly

0 (0.00)

1 (0.01)

Death

30 (0.17)

30 (0.37)

Disability

1 (0.01)

1 (0.01)

Hospitalization-initial or prolonged

27 (0.15)

37 (0.45)

Life-threatening

6 (0.03)

29 (0.35)

Other serious/important medical events

137 (0.78)

54 (0.66)

Required intervention to prevent permanent impairment/damage

2 (0.01)

0 (0.00)